# TRIgnite-1 (NCT05862012)

> Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05862012
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Ichnos Sciences SA
- Conditions: Relapsed/Refractory Multiple Myeloma
- Interventions: ISB 2001; ISB 2001
- Enrollment: 200
- Primary outcome: Frequency and Severity Of Treatment-Emergent Adverse Events (TEAEs)
- Primary outcome: Number of Dose-Limiting Toxicities (DLT) During the First 28 Days After the First Administration of ISB 2001 (Cycle 1) in Each Cohort (Part 1)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 1
- X threads: 1
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=trignite-1-nct05862012